Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Fineline Cube Apr 28, 2026
Company Drug

Merck’s Clesrovimab Gears Up for Priority Review in China for RSV Prevention

Fineline Cube Jun 19, 2025

China’s Center for Drug Evaluation (CDE) website indicates that US giant Merck, Sharp & Dohme’s...

Company Drug

Sanofi’s Tzield Prescribed in Boao Lecheng to Delay Onset of Type 1 Diabetes

Fineline Cube Jun 18, 2025

Tzield (teplizumab), the world’s first and only targeted therapy designed to delay the onset of...

Company Medical Device

Allgens Medical’s SkuHeal Artificial Bone Repair Material Gains Vietnam Marketing Approval

Fineline Cube Jun 18, 2025

Beijing-based regenerative medicine materials and implantable device maker Allgens Medical Technology Co., Ltd (SHA: 688613)...

Company Drug

Clover Biopharmaceuticals Completes Enrollment for Phase I Trial of RSV + hMPV Combination Vaccines

Fineline Cube Jun 18, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the completion of enrollment for the first participants...

Company Deals

Shanghai Henlius Biotech Partners with Shanghai Chest Hospital for Clinical Research and Talent Development

Fineline Cube Jun 18, 2025

China’s Shanghai Henlius Biotech Inc., (HKG: 2696) this week entered into a strategic collaboration agreement...

Company Drug

RemeGen’s Telitacicept Receives Orphan Drug Designation for Myasthenia Gravis in Europe

Fineline Cube Jun 18, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced that it has received orphan drug...

Company Drug

Yunnan Baiyao’s JZ-14 Gets NMPA Clinical Clearance for Ulcerative Colitis Trial

Fineline Cube Jun 18, 2025

Kunming-based Yunnan Baiyao Group Co., Ltd (SHE: 000538), traditionally known for Chinese medicine, announced clinical...

Company Drug

Johnson & Johnson Submits sBLA to Expand Stelara Use for Pediatric Crohn’s Disease

Fineline Cube Jun 18, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) this week submitted a supplemental Biologics License...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG005 and ZG006 Combination Trial in Advanced Cancers

Fineline Cube Jun 18, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Medical Device

Mindray Bio-Medical Expands North American Warehouse to Enhance Operational Efficiency

Fineline Cube Jun 18, 2025

China-based Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) announced the groundbreaking of its North...

Company

GSK Launches ‘Linked by Lupus’ Initiative to Support Lupus Care with $1M Funding

Fineline Cube Jun 18, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the launch of the Linked by Lupus:...

Company Drug

Bayer Files NDA for Gadoquatrane, Aiming to Offer Lowest-Dose GBCA in the U.S.

Fineline Cube Jun 18, 2025

Germany-based Bayer AG (ETR: BAYN) announced that it has made a New Drug Application (NDA)...

Company Deals

EpimAb Biotherapeutics Submits Hong Kong IPO Application as Biotech Expands

Fineline Cube Jun 18, 2025

Shanghai-based biotech EpimAb Biotherapeutics, Inc. has submitted a main board listing application to the Hong...

Company Drug

Sinocelltech Gains NMPA Clearance for SCTB39-1 Clinical Study in Advanced Solid Tumors

Fineline Cube Jun 18, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...

Company Drug

Santen’s Ryjunea Gets EU Approval to Slow Myopia Progression in Children

Fineline Cube Jun 18, 2025

Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from the European...

Company

Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move

Fineline Cube Jun 18, 2025

Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...

Company Deals

Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”

Fineline Cube Jun 18, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has entered into a partnership with China’s Alibaba Health Information...

Company

Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges

Fineline Cube Jun 18, 2025

Reports indicate that China-based Legend Biotech Corporation (NASDAQ: LEGN) plans to disband its China sales...

Company Deals

Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics

Fineline Cube Jun 17, 2025

France-based Pierre Fabre Laboratories announced the acquisition of global rights to PFL-721 and PFL-241 from...

Company Deals

Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers

Fineline Cube Jun 17, 2025

China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization...

Posts pagination

1 … 133 134 135 … 657

Recent updates

  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
  • Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
  • Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Others

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.